Back to News
Market Impact: 0.35
Tiziana Eyes Next Foralumab Milestones After Positive Progressive MS Data; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Tiziana Life Sciences announced positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). The report provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
TLSA0.75
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead